NTLA - Intellia Therapeutics Inc Stock Price, Fair Value and News

26.26USD+0.09 (+0.34%)Delayed

Market Summary

USD26.26+0.09

Delayed

0.34%

NTLA Alerts

Big jump in Revenue (Y/Y)

Losses in recent quarter

NTLA Stock Price

View Fullscreen

NTLA RSI Chart

NTLA Valuation

Market Cap

2.5B

Price/Earnings (Trailing)

-5.22

Price/Sales (Trailing)

69.84

EV/EBITDA

-38.35

Price/Free Cashflow

-6.06

NTLA Price/Sales (Trailing)

NTLA Profitability

EBT Margin

-186.20%

Return on Equity

-46.86%

Return on Assets

-38.54%

Free Cashflow Yield

-16.5%

NTLA Fundamentals

NTLA Revenue

Revenue (TTM)

36.3M

Rev. Growth (Yr)

129.53%

Rev. Growth (Qtr)

41.4%

NTLA Earnings

Earnings (TTM)

-485.5M

Earnings Growth (Yr)

-4.18%

Earnings Growth (Qtr)

18.71%

Breaking Down NTLA Revenue

Last 7 days

7.4%

Last 30 days

22.1%

Last 90 days

-5.3%

Trailing 12 Months

-38.9%

How does NTLA drawdown profile look like?

NTLA Financial Health

Current Ratio

9.03

NTLA Investor Care

Shares Dilution (1Y)

9.46%

Diluted EPS (TTM)

-5.37

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	53.5M	53.0M	51.8M	36.3M
2022	37.9M	45.3M	51.4M	52.1M
2021	51.5M	41.8M	26.8M	33.1M
2020	45.6M	50.7M	62.3M	58.0M
2019	33.4M	36.8M	40.0M	43.1M
2018	27.4M	29.1M	29.2M	30.4M
2017	20.9M	22.6M	25.1M	26.1M
2016	6.5M	9.4M	12.5M	16.5M
2015	0	0	0	6.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Intellia Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 04, 2024	clark eliana	sold	-19,958	32.99	-605	evp, chief technical officer
Mar 04, 2024	basta james	sold	-75,778	32.99	-2,297	evp, general counsel
Mar 01, 2024	goddard glenn	acquired	-	-	28,628	evp, chief financial officer
Mar 01, 2024	hicks derek	acquired	-	-	29,393	evp, chief business officer
Mar 01, 2024	basta james	acquired	-	-	32,394	evp, general counsel
Mar 01, 2024	clark eliana	acquired	-	-	31,230	evp, chief technical officer
Mar 01, 2024	sepp-lorenzino laura	acquired	-	-	37,966	evp, chief scientific officer
Mar 01, 2024	leonard john m	acquired	-	-	113,586	president and ceo
Mar 01, 2024	lebwohl david	acquired	-	-	38,701	evp, chief medical officer
Jan 08, 2024	sepp-lorenzino laura	sold	-65,681	28.8711	-2,275	evp, chief scientific officer

Which funds bought or sold NTLA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-4.33	-372,848	2,352,960	-%
May 16, 2024	Arete Wealth Advisors, LLC	sold off	-100	-220,138	-	-%
May 16, 2024	COMERICA BANK	added	853	902,087	1,020,740	-%
May 16, 2024	JANE STREET GROUP, LLC	reduced	-54.07	-3,647,330	2,581,320	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	added	21.00	1,421,290	16,906,800	0.04%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	new	-	4,920,960	4,920,960	-%
May 15, 2024	CAPTRUST FINANCIAL ADVISORS	sold off	-100	-389,052	-	-%
May 15, 2024	Ghost Tree Capital, LLC	new	-	687,750	687,750	0.19%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-72.49	-83,827	27,675	-%
May 15, 2024	Capital Impact Advisors, LLC	added	22.45	83,484	880,127	1.14%

Are Funds Buying or Selling NTLA?

Are funds buying NTLA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own NTLA

No. of Funds

Unveiling Intellia Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	9.32%	8,347,449	SC 13G/A
Jan 29, 2024	ark investment management llc	12.74%	11,412,449	SC 13G/A
Jan 24, 2024	state street corp	5.29%	4,735,861	SC 13G/A
Jan 08, 2024	blackrock inc.	10.1%	9,010,695	SC 13G/A
Feb 10, 2023	ark investment management llc	11.20%	9,420,782	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 09, 2023	vanguard group inc	9.28%	7,810,226	SC 13G/A
Jan 25, 2023	blackrock inc.	8.7%	7,254,921	SC 13G
Feb 14, 2022	nikko asset management americas, inc.	3.70%	2,753,903	SC 13G/A
Feb 11, 2022	regeneron pharmaceuticals, inc.	4.98%	3,702,995	SC 13G/A

Recent SEC filings of Intellia Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
Apr 29, 2024	ARS	ARS
Apr 29, 2024	DEF 14A	DEF 14A
Apr 29, 2024	DEFA14A	DEFA14A
Apr 22, 2024	3	Insider Trading
Apr 16, 2024	PRE 14A	PRE 14A
Apr 15, 2024	8-K	Current Report
Mar 22, 2024	8-K	Current Report
Mar 05, 2024	4	Insider Trading

Peers (Alternatives to Intellia Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Intellia Therapeutics Inc News

Latest updates

Intellia Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	41.4%	28,935,000	20,463,500	11,992,000	13,594,000	12,606,000	13,573,000	13,266,000	14,030,000	11,252,000	12,854,000	7,204,000	6,550,000	6,445,000	6,595,000	22,220,000	16,263,000	12,916,000	10,936,000	10,616,000	11,118,000	10,433,000
Costs and Expenses	3.6%	142,938,000	137,975,000	143,099,000	145,928,000	124,564,000	123,660,000	118,796,000	112,331,000	155,498,000	93,269,000	79,197,000	75,567,000	52,870,000	48,994,000	50,322,000	49,297,000	45,964,000	40,707,000	35,944,000	38,578,000	34,242,000
S&GA Expenses	-100.0%	-	28,994,000	29,403,000	30,652,000	27,448,000	23,626,000	22,145,000	22,132,000	22,403,000	22,108,000	18,711,000	16,683,000	13,594,000	10,763,000	10,566,000	11,526,000	11,314,000	8,976,000	8,431,000	13,118,000	10,533,000
R&D Expenses	2.6%	111,847,000	108,981,000	113,696,000	115,276,000	97,116,000	100,034,000	96,651,000	90,199,000	133,095,000	71,161,000	60,486,000	58,884,000	39,276,000	38,231,000	39,756,000	37,771,000	34,650,000	31,731,000	27,513,000	25,460,000	23,709,000
EBITDA Margin	0.8%	-1.60	-1.61	-1.14	-1.12	-1.12	-1.15	-1.17	-1.33	-1.60	-1.83	-2.27	-1.46	-	-	-	-	-	-	-	-	-
EBT Margin	0%	-1.86	-1.86	-1.30	-1.27	-1.26	-1.30	-1.31	-1.49	-1.78	-2.04	-2.52	-1.62	-	-	-	-	-	-	-	-	-
Net Income	18.7%	-107,436,000	-132,161,000	-122,224,000	-123,681,000	-103,126,000	-113,407,000	-113,229,000	-100,678,000	-146,872,000	-81,237,000	-71,644,000	-68,806,000	-46,205,000	-42,192,000	-27,840,000	-32,393,000	-31,806,000	-28,276,000	-23,634,000	-25,683,000	-21,940,000
Net Income Margin	-0.9%	-13.38	-13.27	-8.93	-8.55	-8.05	-9.10	-8.60	-8.83	-9.73	-8.10	-8.54	-4.43	-	-	-	-	-	-	-	-	-
Free Cashflow	-30.2%	-123,168,000	-94,574,000	-105,713,000	-94,624,000	-113,160,000	-93,781,000	-82,763,000	-89,071,000	-81,230,000	-57,519,000	-69,560,000	-55,919,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-3.2%	1,260	1,301	1,243	1,323	1,418	1,520	1,084	1,110	1,203	1,294	1,335	672	717	676	459	491	315	334	347	352	344
Current Assets	-11.4%	884	998	893	940	964	1,217	859	895	875	769	815	549	601	617	416	446	270	289	296	307	304
Cash Equivalents	-24.2%	172	227	168	172	294	524	141	148	133	123	335	130	142	160	180	362	81.00	57.00	38.00	49.00	47.00
Net PPE	-2.1%	32.00	33.00	34.00	33.00	32.00	28.00	27.00	26.00	24.00	21.00	20.00	19.00	16.00	16.00	16.00	16.00	17.00	18.00	17.00	17.00	17.00
Liabilities	-10.9%	223	251	206	-	-	285	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Current Liabilities	-15.0%	98.00	115	92.00	100	103	127	131	124	126	126	98.00	74.00	61.00	64.00	56.00	59.00	35.00	36.00	38.00	38.00	39.00
Shareholder's Equity	-1.3%	1,036	1,050	1,037	1,105	1,191	1,236	825	881	954	1,040	1,107	495	546	527	330	352	248	270	276	277	264
Retained Earnings	-6.5%	-1,765	-1,658	-1,526	-1,403	-1,280	-1,177	-1,063	-950	-849	-703	-621	-550	-481	-435	-392	-365	-332	-300	-272	-248	-223
Additional Paid-In Capital	3.4%	2,803	2,711	2,567	2,513	2,474	2,420	1,898	1,841	1,812	1,746	1,729	1,045	1,027	962	723	717	580	570	548	526	488
Shares Outstanding	3.6%	96.00	93.00	89.00	88.00	88.00	87.00	76.00	75.00	75.00	71.00	70.00	68.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	3,565	-	-	-	3,889	-	-	-	10,926	-	-	-	1,183	-	-	-	741	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-29.7%	-120,662	-93,054	-101,381	-90,323	-109,328	-89,869	-78,526	-85,091	-79,801	-54,651	-65,022	-52,981	-52,376	-40,226	-28,558	57,417	-38,545	-28,662	-25,448	-27,677	-21,453
Share Based Compensation	-2.5%	34,176	35,043	35,352	36,400	27,255	24,626	25,215	23,068	18,491	14,561	15,410	10,614	6,424	5,582	5,400	4,764	4,157	3,016	3,079	4,404	4,592
Cashflow From Investing	-87.2%	5,901	45,939	79,500	-34,538	-122,248	-30,152	47,643	95,345	47,473	-159,115	-399,381	33,260	-25,542	-210,918	-153,980	92,963	57,448	27,884	-31,652	23,249	5,695
Cashflow From Financing	-43.7%	59,992	106,484	19,102	2,516	2,221	505,763	23,977	5,895	47,320	2,280	668,680	7,133	58,595	234,093	597	132,225	4,864	19,564	46,400	6,471	3,999

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

NTLA Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Collaboration revenue	$ 28,935	$ 12,606
Type of Revenue [Extensible List]	us-gaap:LicenseAndServiceMember	us-gaap:LicenseAndServiceMember
Operating expenses:
Research and development	$ 111,847	$ 97,116
General and administrative	31,091	27,448
Total operating expenses	142,938	124,564
Operating loss	(114,003)	(111,958)
Other income (expense), net:
Interest income	12,632	11,980
Change in fair value of investments, net	(6,065)	0
Loss from equity method investment	0	(3,048)
Change in fair value of contingent consideration	0	(100)
Total other income (expense), net	6,567	8,832
Net loss	$ (107,436)	$ (103,126)
Net loss per share, basic	$ (1.12)	$ (1.17)
Net loss per share, diluted	$ (1.12)	$ (1.17)
Weighted average shares outstanding, basic	95,502	87,772
Weighted average shares outstanding, diluted	95,502	87,772
Other comprehensive (loss) gain:
Unrealized gain (loss) on marketable securities	$ (821)	$ 2,989
Other comprehensive gain - equity method investment	0	1,794
Comprehensive loss	$ (108,257)	$ (98,343)

NTLA Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 171,979	$ 226,748
Marketable securities	619,315	685,475
Accounts receivable	36,427	36,456
Prepaid expenses and other current assets	56,322	49,651
Total current assets	884,043	998,330
Marketable securities - noncurrent	162,090	99,864
Property and equipment, net	32,075	32,760
Operating lease right-of-use assets	110,424	115,375
Equity method investment	0	11,765
Investments and other assets	70,957	42,883
Total assets	1,259,589	1,300,977
Current liabilities:
Accounts payable	13,689	7,452
Accrued expenses	43,276	67,017
Current portion of operating lease liability	18,763	18,599
Current portion of deferred revenue	22,184	22,140
Total current liabilities	97,912	115,208
Deferred revenue, net of current portion	33,440	38,853
Long-term operating lease liability	92,100	96,747
Total liabilities	223,452	250,808
Commitments and contingencies (Note 6)
Stockholders' equity:
Common stock, $0.0001 par value; 240,000,000 shares authorized at March 31, 2024 and December 31, 2023; 96,333,373 and 92,997,158 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	10	9
Additional paid-in capital	2,802,889	2,710,797
Accumulated other comprehensive loss	(947)	(2,258)
Accumulated deficit	(1,765,815)	(1,658,379)
Total stockholders’ equity	1,036,137	1,050,169
Total liabilities and stockholders' equity	$ 1,259,589	$ 1,300,977

About Intellia Therapeutics Inc

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as for other product candidates, including NTLA-2003 for alpha-1 antitrypsin deficiency-liver disease; and NTLA-3001 for alpha-1 antitrypsin deficiency-lung disease; and NTLA-6001 for CD30+ lymphomas. It also focus on programs comprising hemophilia A and hemophilia B; ex vivo pipeline including NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Further, the company has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; and AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; and SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. Additionally, it has license and coloration agreement with Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. to develop optimally engineered natural killer cell therapies to cure patients with cancer; and Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

CEO	Dr. John M. Leonard M.D.
WEBSITE	intelliatx.com
INDUSTRY	Biotechnology
EMPLOYEES	598

Intellia Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Intellia Therapeutics Inc? What does NTLA stand for in stocks?

NTLA is the stock ticker symbol of Intellia Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Intellia Therapeutics Inc (NTLA)?

As of Fri May 17 2024, market cap of Intellia Therapeutics Inc is 2.53 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NTLA stock?

You can check NTLA's fair value in chart for subscribers.

What is the fair value of NTLA stock?

You can check NTLA's fair value in chart for subscribers. The fair value of Intellia Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Intellia Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NTLA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Intellia Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether NTLA is over valued or under valued. Whether Intellia Therapeutics Inc is cheap or expensive depends on the assumptions which impact Intellia Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NTLA.

What is Intellia Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, NTLA's PE ratio (Price to Earnings) is -5.22 and Price to Sales (PS) ratio is 69.84. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NTLA PE ratio will change depending on the future growth rate expectations of investors.